+38.6%
GILD vs MRNA
+907.1%
-868.5%
-21.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.4% | +5.3% | -5.7% | -0.6% |
| 7D | -2.2% | +14.6% | -16.9% | -2.6% |
| 30D | +13.6% | +29.4% | -15.7% | +12.6% |
| 3M | +28.3% | +371.9% | -343.7% | +19.4% |
| 6M | +23.9% | +421.0% | -397.0% | +13.7% |
| YTD | +38.4% | +762.0% | -723.5% | +20.1% |
| 1Y | +38.6% | +944.8% | -906.2% | +17.0% |
| All | +38.6% | +907.1% | -868.5% | +17.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling